LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 101 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,270 | -5.7% | 29,890 | +12.7% | 0.00% | – |
| Q2 2023 | $37,393 | -91.1% | 26,520 | -90.5% | 0.00% | – |
| Q1 2023 | $419,654 | +2447.7% | 279,769 | +1887.1% | 0.00% | – |
| Q4 2022 | $16,472 | -3.1% | 14,079 | -9.0% | 0.00% | – |
| Q3 2022 | $17,000 | -86.6% | 15,473 | -80.7% | 0.00% | – |
| Q2 2022 | $127,000 | -35.2% | 80,169 | -37.1% | 0.00% | – |
| Q1 2022 | $196,000 | -19.0% | 127,432 | +29.2% | 0.00% | – |
| Q4 2021 | $242,000 | -1.2% | 98,659 | +1.6% | 0.00% | – |
| Q3 2021 | $245,000 | +544.7% | 97,071 | +625.8% | 0.00% | – |
| Q2 2021 | $38,000 | -91.9% | 13,374 | -93.3% | 0.00% | – |
| Q1 2021 | $467,000 | +344.8% | 198,638 | +64.3% | 0.00% | – |
| Q2 2020 | $105,000 | +94.4% | 120,899 | +84.0% | 0.00% | – |
| Q1 2020 | $54,000 | -38.6% | 65,710 | -33.5% | 0.00% | – |
| Q4 2019 | $88,000 | +100.0% | 98,833 | +119.1% | 0.00% | – |
| Q3 2019 | $44,000 | – | 45,112 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $41,223,872 | 3.66% |
| Raffles Associates | 1,587,739 | $1,873,532 | 2.48% |
| Defender Capital, LLC. | 5,184,510 | $6,117,722 | 2.22% |
| Prescott General Partners LLC | 1,851,851 | $2,185,184 | 0.14% |
| DCF Advisers, LLC | 82,751 | $97,646 | 0.05% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $63,450 | 0.05% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $922,484 | 0.02% |
| Fort Sheridan Advisors LLC | 83,931 | $99,039 | 0.02% |
| MAI Capital Management | 954,688 | $1,126,532 | 0.02% |
| Piscataqua Savings Bank | 12,499 | $14,623 | 0.01% |